Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Unknown 24Recruiting 18Not yet recruiting 12Completed 4Active not recruiting 2Suspended 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 3Thoracic 1

Conditions

Solid Tumors 2Carcinoma, Non-Small-Cell Lung 1Advanced or Metastatic Solid Tumors 1

Interventions

Cyclophosphamide 1492Cisplatin 1414Paclitaxel 1317Radiotherapy 1261Carboplatin 1250Gemcitabine 1215Docetaxel 1109Bevacizumab 1030Fluorouracil 894Doxorubicin 792Dexamethasone 748Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 680Etoposide 678Irinotecan 634Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 558Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 427Pemetrexed 420

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Interventional × envafolimab × Clear all
NCT05068427 2024-08-07

Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.

Chipscreen Biosciences, Ltd.

Phase 2 Completed
34 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03101488 2022-03-03

Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors

3D Medicines

Phase 1 Completed
287 enrolled
Other solid neoplasm

Solid Tumors

NCT03248843 2022-02-08

A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors

3D Medicines

Phase 1 Completed
35 enrolled
Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT02827968 2021-06-02

Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors

3D Medicines

Phase 1 Completed
28 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡